Senseonics Holdings, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for November 7, 2024 at 4:30 P.M. Eastern Time
Senseonics Holdings (NYSE American: SENS), a medical technology company developing long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its upcoming third quarter 2024 financial results release. The results will be disclosed after market close on Thursday, November 7, 2024, followed by a conference call at 4:30 p.m. Eastern Time. Investors can access the webcast through the company's website or join via phone using the provided dial-in numbers.
Senseonics Holdings (NYSE American: SENS), un'azienda di tecnologia medica che sviluppa sistemi di monitoraggio continuo della glicemia impiantabili a lungo termine per pazienti diabetici, ha annunciato il rilascio dei risultati finanziari del terzo trimestre 2024. I risultati saranno divulgati dopo la chiusura del mercato giovedì 7 novembre 2024, seguiti da una conference call alle 16:30 ora orientale. Gli investitori possono accedere al webcast attraverso il sito web dell'azienda o partecipare telefonicamente utilizzando i numeri di accesso forniti.
Senseonics Holdings (NYSE American: SENS), una empresa de tecnología médica que desarrolla sistemas de monitoreo continuo de glucosa implantables a largo plazo para pacientes diabéticos, ha anunciado la próxima presentación de sus resultados financieros del tercer trimestre de 2024. Los resultados se darán a conocer después del cierre del mercado el jueves 7 de noviembre de 2024, seguido de una conferencia telefónica a las 4:30 p.m. hora del Este. Los inversores pueden acceder al webcast a través del sitio web de la empresa o unirse por teléfono utilizando los números de marcación proporcionados.
센소닉스 홀딩스 (NYSE American: SENS), 당뇨병 환자를 위한 장기 이식형 연속 포도당 모니터링 시스템을 개발하는 의료 기술 회사가 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 결과는 2024년 11월 7일 목요일 시장 종료 후 공개되며, 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜이 이어집니다. 투자자들은 회사 웹사이트를 통해 웹캐스트에 접속하거나 제공된 전화 번호를 통해 참여할 수 있습니다.
Senseonics Holdings (NYSE American: SENS), une entreprise de technologie médicale développant des systèmes de surveillance continue de la glycémie implantables à long terme pour les patients diabétiques, a annoncé la prochaine publication de ses résultats financiers du troisième trimestre 2024. Les résultats seront révélés après la fermeture du marché le jeudi 7 novembre 2024, suivis d'une conférence téléphonique à 16h30, heure de l'Est. Les investisseurs peuvent accéder au webinaire via le site web de l'entreprise ou participer par téléphone en utilisant les numéros d'accès fournis.
Senseonics Holdings (NYSE American: SENS), ein Medizintechnikunternehmen, das implantierbare kontinuierliche Blutzuckermesssysteme für Diabetespatienten entwickelt, hat die bevorstehende Veröffentlichung der finanziellen Ergebnisse für das dritte Quartal 2024 angekündigt. Die Ergebnisse werden nach Börsenschluss am Donnerstag, den 7. November 2024 bekannt gegeben, gefolgt von einer Telefonkonferenz um 16:30 Uhr Eastern Time. Investoren können über die Website des Unternehmens auf den Webcast zugreifen oder sich telefonisch über die bereitgestellten Einwahlnummern einwählen.
- None.
- None.
GERMANTOWN, Md., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, November 7, 2024.
Management will hold a conference call to review the Company’s third quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-445-7795 (US/Canada) or 1-203-518-9856 (International), passcode SENSQ3, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
FAQ
When will Senseonics (SENS) release Q3 2024 earnings?
What time is Senseonics (SENS) Q3 2024 earnings call?
How can I listen to Senseonics (SENS) Q3 2024 earnings call?
